Synendos Therapeutics was incorporated in April 2019 as spin-off company of the University of Bern and as first spin-off company of the drug discovery consortium NCCR TransCure.


Synendos stems from 10 years of solid basic research on endocannabinoid biology and pharmacology carried out at the University of Bern by Prof. Jürg Gertsch and Dr. Andrea Chicca.

Management & Executive team


Dr. Andrea Chicca, Chief Executive Officer and Chief Scientific Officer

Andrea holds a Ph.D. in Pharmacology from the University of Pisa (Italy). After his first post-doctoral studies in cancer biology at the Istituto Toscano Tumori (Firenze, Italy), Andrea joined the group of Prof. J. Gertsch at the University of Bern, initially working as post-doctoral scientist, then senior scientist and principal investigator.

​​In 2018, Andrea obtained the venia docendi in Biochemistry and Molecular Medicine awarded from the Medical Faculty of the University of Bern and obtained the habilitation for professorship in Pharmacology from the Italian Ministry of Education and Research. In 2020, Andrea completed the Master of Advanced Studies in Translational Medicine and Biomedical Entrepreneurship (Sitem-Insel-University of Bern). Andrea is co-author of 50+ scientific articles published in international peer-reviewed journals. 

​​He strongly contributed to the elucidation of the endocannabinoid membrane transport mechanism and the development of SERIs of the first and second generation. Andrea is co-inventor on a granted patent covering SERIs of the first generation in the US.

​Before joining the University of Bern, Andrea worked for almost two years as a scientific advisor in the corporate marketing of Chiesi Pharmaceuticals (Parma, Italy), where he acquired hands-on experience in preclinical and clinical drug development.

​Andrea Chicca is a co-founder, CEO and CSO of Synendos Therapeutics.

Dr. Daniela Alberati, Head of Preclinical and Translation Neuropharmacology

Daniela holds a Ph.D. in Biochemistry and Enzymology from the University of Milan (Italy).

Daniela, spent 20+ years in pharmaceutical research and early development in Neuroscience at Hoffmann-La Roche, holding different leading positions as Head of the Neurochemistry, Senior Scientific Advisor and Vice-Director.  As project leader of multiple programs across psychiatric, neurodevelopmental, and neurodegenerative indications, Daniela has a proven track record of several NMEs reaching different clinical stages of development to treat psychiatric diseases. Daniela crucially contributed to advance the development of the glycine transport inhibitor type 1, bitopertin. Additionally, she has excellent experience with supporting global strategy campaigns and medical affairs. Daniela has taken part of several advisory boards and international congresses in neurobiology/pathophysiology in psychiatry. She also served as a permanent member of the research governance committee evaluating project portfolio from project proposal to entry-into-human stage. 

Beyond her role as project leader, Daniela chaired the Research and Domain Criteria (RDoC) working group composed of preclinical, clinical and biomarker experts to implement this recently National Institute of Mental Health (NIMH) launched research approach with the aim to support translational research in mental illnesses and increase the probability of success in phase 2 studies.

Before joining Synendos, Daniela worked for a few years as Neuroscience and R&D Consultant for venture capitals and start-ups.

Daniela Alberati.jpg
gw6 (1).jpg

Dr. Debora Schmitz-Rohmer, Head of Translational Medicine

Debora holds a Ph.D. in Biochemistry from the University of Basel (Switzerland), a diploma of advanced studies in Pharmaceutical Medicine and Drug Development from the University of Basel (ECPM) and a Master’s degree / DEA in Biotechnology from the Ecole Supérieure de Biotechnologie de Strasbourg (ESBS) (France).


Debora completed her academic training with a postdoc at the Friedrich Miescher Institute (affiliated with the Novartis Institute for Biomedical Research) in Basel (Switzerland). 


Debora joins from Tolremo Therapeutics, where she led and coordinated clinical development planning and the corresponding IND-enabling program. In her earlier roles with Piqur Therapeutics, Debora led the cross-functional team to design and execute the clinical development plan from preclinic until the completion of two PoC (Ph2) studies. Prior to taking on leadership roles, she worked in several functions spanning translational science, clinical science, and pharmacology in close collaboration with regulatory, preclinical and medical / safety.


She complements the Synendos team with hands-on drug development experience in the biotech start-up setting.

Board of Directors


Prof. Dr. Jutta Heim, Chairperson of the Board

Jutta worked for more than 20 years at Ciba-Geigy/Novartis (CH and US). At Novartis, she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. Jutta completed her career at Novartis heading the Novartis Lead Discovery Center with worldwide responsibility.

From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd. a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she served as CTO and CSO at Evolva SA, where she led Evolva’s discovery activities and strengthened the development of its technology platform.

Jutta is a board member of Union Therapeutics, Copenhagen and a member of the scientific advisory board of the Helmholtz Center for infection research, Braunschweig.
Jutta received a Ph.D. from the University of Tübingen in 1981 and holds a professorship in Biotechnology at the Biocenter of the University of Basel.

Dr. Peter Neubeck

Peter is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School and holds an MBA from INSEAD. After tenures at Großhadern University Clinic, Cleveland Clinic, and Beth Israel Deaconess Hospital followed by McKinsey & Company and several leadership positions at Novartis, he entered the Venture Capital industry. He took on responsibilities as an Investment Manager and collected valuable operational experience in various executive roles in company creations. Since January 2019 he heads the investment business of Kurma Partners in Germany.

SoerenL lille.jpg

Dr. Søren Lemonius

Søren is Managing General Partner and one of the three co-founders of Sunstone Life Science Ventures. He has particular focus on Investor relations and therapeutics.
Søren has 18 years’ experience from corporate management in R&D-intensive companies. As Innovation Manager at FOSS Analytical (a food diagnostics company), Søren successfully implemented new analytical technologies.

Prior to joining Sunstone, Søren served as Chief Technology Officer at Danionics (an electronic component company) where he participated in developing the company from a private, 30-employee, venture-backed technology company to a EUR +27 million revenue, +300-employee, listed company.

Søren holds a master’s degree in Experimental Cell Biology from the University of Southern Denmark.​​

Dr. Bettina Ernst

Dr. Bettina Ernst is a biotech entrepreneur and investor. She has expert knowledge in immunology acquired in different academic positions in Europe and the U.S. and has since worked in the biotechnology and pharmaceutical industries. Bettina is a serial biotech entrepreneur and currently serves on the Board of Directors of several biotech companies.

Bettina Ernst.png

Dr. Raúl Martín-Ruiz

Raúl Martín-Ruiz is a Partner in Ysios Capital, a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially working in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors.

Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council).

Other than Synendos Therapeutics, he is a Board member of CorWave, Chairman of Anaconda Biomed and former Board member of STAT-Dx (acquired by Qiagen), Prexton Therapeutics (acquired by Lundbeck) and MedLumics. He has a B.Sc. in Biological Sciences by the UPV-EHU and holds a Ph.D. in Neurosciences by the same university and the CSIC.

Dr. Andrea Chicca

Andrea is a co-founder of Synendos Therapeutics and serves as Chief Executive Officer and Chief Scientific Officer in the company.

Simon Russell 1_modificato.jpg

Dr. Simon Russell

​​Simon has over 30 years’ experience in both Biotech and Big Pharma across strategic marketing and scientific roles, over a wide range of therapy areas and phases. He is currently Chief Business Officer at  OMEICOS Therapeutics GmbH, a Berlin based biotech, responsible for all commercial and business activities. He is also an Entrepreneur-in-Residence at the BaseLaunch accelerator programme advising new ventures in the Basel area. 


He was previously Chief Business Officer at Creabilis Ltd, taking it through a series of deals and financing before negotiating its sale to Sienna Bio-pharmaceuticals Inc in the US in December 2016.  With Sienna he supported the subsequent listing of Sienna on NASDAQ in July 2017.


In his Big Pharma career, he has held senior global commercial roles at both Novartis as Head of Strategic Marketing for Biologics and AstraZeneca in Switzerland, Sweden and the UK, taking several products through Phase III and launch and defining development strategies for many early products across a wide range of therapy areas. Earlier he held significant R&D roles in Clinical Development, Development Management and Medicinal Chemistry.


He holds a PhD in Organic Chemistry from Southampton University and an MA in Chemistry from the University of Oxford in the UK.

Simon is a co-founder of Synendos Therapeutics.

Scientific Advisor Board


Prof. Dr. Karl-Heinz Altmann

Professor Karl-Heinz Altmann is a Professor of Pharmaceutical Biology and Chairman of the Department of Chemistry and Applied Biosciences at the Swiss Federal Institute of Technology (ETH) in Zurich.


Karl-Heinz is a co-founder of Tolremo Therapeutics and serves on several scientific advisory boards and as a consultant to various pharmaceutical companies. He was Project Leader, Senior Chemistry Expert and Global Head of Chemistry at the Novartis Institutes for Bio Medical Research from 1997 to 2003. He was awarded the Novartis Leading Scientist award in 1997 and the Paul-Ehrlich Prize (Chemistry) of the Société de Chimie Thérapeutique, France, in 2014.


In addition, Karl-Heinz has been an academic collaborator on SERI development (1st generation).

Prof. Dr. Anahita Bassir Nia

Professor Anahita Bassir Nia is an Addiction Psychiatrist and Assistant Professor of Psychiatry at Yale School of Medicine, Connecticut, USA.


Anahita’s research mainly focuses on the endocannabinoid system in relation to stress, trauma and substance use disorders. She is associated with the National Centers for Post-Traumatic Stress Disorder in the USA, and is a member of the American Academy of Addiction Psychiatry (Cannabis Interest Committee); the American Society of Clinical Psychopharmacology; the Society of Biological Psychiatry; and the American Psychiatric Association.

Anahita Bassir Nia.jpg
unnamed (1).jpg

Dr. Graeme Bilbe

Dr. Graeme Bilbe is involved in advisory roles to public health institutions, universities and commercial organisations. He is former Research and Development Director and current Scientific Advisor at the Drugs for Neglected Diseases initiative (DNDi), an international non-profit organisation developing safe, effective and affordable treatments for the most neglected patients.


He was Global Head of Neuroscience Discovery at Novartis where he was tasked with the discovery and early development of proof-of-concept of novel treatments for brain diseases. He served as Head of Research for the Neuroscience Franchise at Novartis, and chaired the Neuroscience Disease Area Decision Board where, during his leadership, new therapies for Alzheimer’s disease and an orally active drug for multiple sclerosis, Gilenya, were registered.


Graeme has excellent experience as Chairman of Scientific Advisory Boards for biotechnology companies, charities, funding agencies and university/company consortia.

Prof. Dr. Jürg Gertsch

Professor Jürg Gertsch is Deputy and Co-director of the Institute of Biochemistry and Molecular Medicine at the University of Bern and Full Professor of Biochemistry and Pharmaceutical Biology.


His research was instrumental in the design and development of SERIs and he is an inventor of the SERI technology. He co-founded Synendos and identified the drug target of SERIs.


Jürg has been a scientific advisor in preclinical drug discovery in different companies and is in the management board of NCCR TransCure, where he promotes Knowledge and Technology Transfer (KTT) activities.


Prof. Dr. Kirsten Müller-Vahl

Professor Kirsten Müller-Vahl is Professor of Psychiatry at the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hannover Medical School, Germany (MHH).


A specialist in both, neurology and adult psychiatry, she has been Head of the Tourette’s Syndrome (TS) outpatient department at MHH since 1995. Kirsten is President of the European Society of the Study of Tourette’s Syndrome (ESSTS) and Chairwoman of both the National German Association for Cannabinoid Medicine (ACM) and the International Association for Cannabinoid Medicines (IACM). Kirsten has published more than 160 scientific articles and is a prolific author of guidelines for treating TS in both the EU and US. Moreover, she has been involved in all major TS clinical trials with cannabis, cannabinoids, and other endocannabinoid system modulators.